Le Lézard
Classified in: Health
Subject: PER

Collagen Matrix, Inc. Names Gregory Pomrink as Vice President, Research and Development


OAKLAND, N.J., March 21, 2018 /PRNewswire/ -- Collagen Matrix, Inc., a leader in regenerative medicine and a global manufacturer of collagen and mineral based medical devices, announced today the appointment of Gregory Pomrink as Vice President, Research and Development to further leverage its six proprietary technologies across the company's five key business units in Dental, Spine, Orthopaedic, Dural Repair and Nerve Repair Surgery.

Gregory Pomrink, Collagen Matrix, Inc. VP R&D

Greg joins the Collagen Matrix executive team as an accomplished medical device executive with over 30 years of extensive experience designing, developing and commercializing medical devices for the regeneration of bone and soft tissues.  "We are pleased to add Greg to our team as we continue to drive product development across our portfolio. Greg's experience and knowledge will strengthen our executive team and I look forward to expanding our product pipeline across the various technology platforms that underlie Collagen Matrix," said Bart J. Doedens, CEO of Collagen Matrix Inc.

Prior to joining Collagen Matrix, Greg held various Research and Development roles with LifeNet Health, NovaBone Products, Integra LifeSciences, Dentsply and Orthovita specializing in products for dentistry, sports medicine, orthopaedics/spine, and neurosurgery along with plastic and reconstructive surgery applications.  Greg has a Bachelor of Arts degree in Chemistry from Temple University along with a Master of Science degree in Chemistry from Lehigh University and a Master of Business Administration degree from Eastern University.

About Collagen Matrix
Collagen Matrix, Inc., founded in 1997, delivers a full line of the highest-quality collagen and mineral based medical devices that support the body's natural ability to regenerate.  The Company currently manufactures finished medical devices in the areas of Dental, Spine, Orthopaedic, Dural Repair and Nerve Repair Surgery.  The evolution of the Company's leadership, proprietary technologies, manufacturing expertise and product portfolio has established a solid foundation for continued growth. Opportunities continue to exist for collaboration through Product Distribution, Product Development and Contract Manufacturing.  More information about Collagen Matrix can be found at www.CollagenMatrix.com.

Contact: Margo Lane
201-405-1477
[email protected]

 

SOURCE Collagen Matrix, Inc.


These press releases may also interest you

at 16:05
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today...

at 16:05
Stevanato Group S.p.A. , a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the first...

at 16:05
Bruker Corporation today announced it will report first quarter 2024 financial results before market opening on Thursday, May 2, 2024. The Company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the results and current...

at 16:05
Gilead Sciences, Inc. announced today its first quarter 2024 results of operations. "Gilead delivered another strong quarter of revenue growth in the first quarter with 6% year-over-year growth in our base business driven by HIV, Oncology and...

at 16:05
DexCom, Inc. today reported its financial results as of and for the quarter ended March 31, 2024. First Quarter 2024 Financial Highlights: Revenue grew 24% year-over-year to $921.0 million on a reported basis and 25% year-over-year on an...

at 16:05
Ironwood Pharmaceuticals, Inc. today announced it will host its first quarter 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, May 9, 2024. Individuals interested in participating in the call should dial (888)...



News published on and distributed by: